

TuHURA Biosciences, Inc./NV (HURA)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001498382

TuHURA Biosciences, Inc./NV		
HURA; healthcare		
Grade	None 2 of 14 inputs computable; 7 are required	Share price, twelve months to the rescansplit-adjusted close; the letter is fixed at the rescans that set it 
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025	
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$12.5M to \$120M assets total assets \$27.4M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	short runway, thin data, degenerate inputs; fortress balance sheet not computable: dilution, distress	
Inputs computable	2 of 14	
Graded from	filings received through Apr 30, 2026 162 days before the rescans; latest periodic filing 10-Q received Aug 14, 2026	
Last close	\$1.95 2026-10-08; market equity \$124.3M	
Price used in grade	None	

Letter at every rescansJan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's wordsopening of Item 1 of the 10-K received Mar 31, 2026

We are a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. Our proprietary Immune Fx™ technology platform, or IFx, is an innate immune agonist technology designed to "trick" the body's immune system to attack tumor cells by making tumor cells look like bacteria. Our lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.

The fourteen inputslower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 40.7						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			required facts have no common fiscal period end
Accruals ratio		(10.2%)	(6.6%)	40.7	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 91.4						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		not computable	(0.31)			required facts have no common fiscal period end
Net debt to EBITDA		not computable	1.82x			required facts have no common fiscal period end
Interest coverage		not computable	(4.51x)			required facts have no common fiscal period end
Current ratio		0.78x	2.96x	91.4	839	2025-12-31
Growth and financing						
Revenue growth, three-year compound		not computable	10.0%			four annual observations are required; found 3
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 2
Reinvestment rate		not computable	37.1%			required facts have no common fiscal period end
Asset growth, three years		not computable	2.1%			four consecutive annual observations are required
Net share issuance, one year		not computable	2.5%			prior share count is 32 days earlier

Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 0.4 months
Thin data	2 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor
Fortress balance sheet	cash minus debt is 5,970,878 USD; Altman Z is not used

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(14.1%)	8.0%	36
Distance from 52-week high	(38.7%)	(31.4%)	39
EBIT to enterprise value	(0.02%)	(1.5%)	55
Free cash flow yield	(22.5%)	(1.0%)	21
Book value to price	0.15	0.28	35
Sales to price	0.00	0.31	0
Composite equity issuance, five years	785.7%	20.3%	99
Relative strength against the sector, log excess return	(0.36)	(0.14)	36

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$995,977
Operating cash flow, four quarters	-\$29.7M
Months of runway	0.4
Days since last periodic filing	56 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	\$409,331

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$30.1M	2025-12-31	2026-03-31	10-K	0001193125-26-134950
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$27.6M	2025-12-31	2026-03-31	10-K	0001193125-26-134950
3	assets	us-gaap:Assets	\$27.4M	2025-12-31	2026-03-31	10-K	0001193125-26-134950
4	assets	us-gaap:Assets	\$20.0M	2024-12-31	2026-03-31	10-K	0001193125-26-134950
5	current assets	us-gaap:AssetsCurrent	\$4.6M	2025-12-31	2026-03-31	10-K	0001193125-26-134950
6	current liabilities	us-gaap:LiabilitiesCurrent	\$5.9M	2025-12-31	2026-03-31	10-K	0001193125-26-134950
7	revenue	us-gaap:Revenues	\$0	2025-12-31	2026-03-31	10-K	0001193125-26-134950
8	revenue	us-gaap:Revenues	\$0	2024-12-31	2026-03-31	10-K	0001193125-26-134950
9	revenue	us-gaap:Revenues	\$0	2012-06-30	2012-12-20	10-K/A	0001165527-12-001331
10	assets	us-gaap:Assets	\$6.2M	2024-06-30	2024-10-07	10-K	0000950170-24-113321
11	assets	us-gaap:Assets	\$4.0M	2023-06-30	2024-10-07	10-K	0000950170-24-113321
12	shares outstanding	dei:EntityCommonStockSharesOutstanding	63,682,528	2026-04-24	2026-04-30	10-K/A	0001193125-26-197486
13	shares outstanding	dei:EntityCommonStockSharesOutstanding	63,578,528	2026-03-23	2026-03-31	10-K	0001193125-26-134950